Cargando…

Mapping brain networks in MPS I mice and their restoration following gene therapy

Mucopolysaccharidosis type I (MPS I) is an inherited lysosomal disorder that causes syndromes characterized by physiological dysfunction in many organs and tissues. Despite the recognizable morphological and behavioral deficits associated with MPS I, neither the underlying alterations in functional...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Wei, Ou, Li, Zhang, Lin, Clark, Isaac H., Zhang, Ying, Zhu, Xiao-Hong, Whitley, Chester B., Hackett, Perry B., Low, Walter C., Chen, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404260/ https://www.ncbi.nlm.nih.gov/pubmed/37543633 http://dx.doi.org/10.1038/s41598-023-39939-0

Ejemplares similares

Genotype‐phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry
por: Clarke, Lorne A., et al.
Publicado: (2019)

Phenotype prediction for mucopolysaccharidosis type I by in silico analysis
por: Ou, Li, et al.
Publicado: (2017)

Differences in MPS I and MPS II Disease Manifestations
por: Hampe, Christiane S., et al.
Publicado: (2021)

Assessment of Dysmyelination with RAFFn MRI: Application to Murine MPS I
por: Satzer, David, et al.
Publicado: (2015)

The natural history of MPS I: global perspectives from the MPS I Registry
por: Beck, Michael, et al.
Publicado: (2014)

A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II
por: Shapiro, Elsa G., et al.
Publicado: (2016)

Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I
por: Ou, Li, et al.
Publicado: (2016)

Growth patterns for untreated individuals with MPS I: Report from the international MPS I registry
por: Viskochil, David, et al.
Publicado: (2019)

Reduction of lysosome abundance and GAG accumulation after odiparcil treatment in MPS I and MPS VI models
por: Tuyaa-Boustugue, Pascale, et al.
Publicado: (2023)

Weaknesses of the MPS
por: Holzer, B
Publicado: (2009)

Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing
por: Laoharawee, Kanut, et al.
Publicado: (2018)

Part I - Technical specification for MPS CAMAC module dual preset counter CDPC MPS 2001 R/I-7980
Publicado: (1974)

The essential roles of Mps1 in spermatogenesis and fertility in mice
por: Fang, Qiang, et al.
Publicado: (2021)

Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice
por: Morimoto, Hideto, et al.
Publicado: (2021)

On the history of the mps/co operation
por: Madsen, J. H. B
Publicado: (1973)

Blood-brain barrier impairment in MPS III patients
por: Garbuzova-Davis, Svitlana, et al.
Publicado: (2013)

Brain Pathology in Mucopolysaccharidoses (MPS) Patients with Neurological Forms
por: Viana, Gustavo M., et al.
Publicado: (2020)

Part II - Production specification for MPS CAMAC module dual preset counter CDPC MPS 2001 R/I-7980
Publicado: (1974)

Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
por: D’Aco, Kristin, et al.
Publicado: (2012)

Sexual behaviour in a murine model of mucopolysaccharidosis type I (MPS I)
por: Barbosa Mendes, Ana, et al.
Publicado: (2019)

Increased Longevity and Metabolic Correction Following Syngeneic Bone Marrow Transplantation in a Murine Model of Mucopolysaccharidosis Type I
por: Wolf, Daniel A., et al.
Publicado: (2011)

Genotype-phenotype correlation of gangliosidosis mutations using in silico tools and homology modeling
por: Ou, Li, et al.
Publicado: (2019)

Substrate Deprivation Therapy to Reduce Glycosaminoglycan Synthesis Improves Aspects of Neurological and Skeletal Pathology in MPS I Mice
por: Derrick-Roberts, Ainslie L. K., et al.
Publicado: (2017)

Capturing phenotypic heterogeneity in MPS I: results of an international consensus procedure
por: de Ru, Minke H, et al.
Publicado: (2012)

Maternal mosaicism for IDUA deletion clarifies recurrence risk in MPS I
por: Breen, Catherine, et al.
Publicado: (2016)

Compact quadrupole (MPS 4010-000-0)
por: Szeless, B
Publicado: (1973)

Proton Synchrotron (MPS)
Publicado: (1964)

Proton Synchrotron (MPS)
Publicado: (1965)

Mps progress report
por: Rodgers, N
Publicado: (1970)

MPS progress report
por: Rodgers, N
Publicado: (1969)

Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI
por: Ahmed, Alia, et al.
Publicado: (2016)

Blood-Brain Barrier Impairment in an Animal Model of MPS III B
por: Garbuzova-Davis, Svitlana, et al.
Publicado: (2011)

Technical specification for MPS CAMAC module dual preset counter CDPC MPS 2001
por: Boucheron, J
Publicado: (1974)

Specification concerning condenser bank: Technical Specification No. 111 (I-4391/MPS)
Publicado: (1966)

Specification for thyristors to be used in magnet power supplies (I/4796/MPS/ED)
Publicado: (1967)

Ataluren suppresses a premature termination codon in an MPS I-H mouse
por: Wang, Dan, et al.
Publicado: (2022)

CERN MPS PDS1 Assembly Language PDSA
por: Carpenter, B
Publicado: (1971)

Mps1 is SUMO-modified during the cell cycle
por: Restuccia, Agnese, et al.
Publicado: (2015)

Cascade counter MPS 2777
por: Barbalat, O
Publicado: (1965)

MPS status report No. 67
por: Henny, L, et al.
Publicado: (1964)

Cannot write session to /tmp/vufind_sessions/sess_l06m4fk8ra413fega7juh62bi6